Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI

{
  "signal_id": "146d7ea1-a27e-eec3-916f-dcf6eaad30b1",
  "signal_type": "news",
  "signal_subtype": "integrates_with",
  "detected_at": "2026-07-08T12:52:00+00:00",
  "company": {
    "name": "Quest Diagnostics",
    "domain": "questdiagnostics.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/quest-diagnostics-now-the-largest-clinical-reference-lab-to-extend-oncology-test-access-through-oncoemr-mpi-302819760.html",
    "title": "Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI",
    "excerpt": "American Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRD SECAUCUS, N.J. , July 8, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX ), a leading provider of diagnostic information services, today announced it is integrating its Haystack MRD ® ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR ® , an electronic health record (EHR) from Flatiron Health, via a pilot program with American Oncology Network (AON) and other community oncology providers. Flatiron Health is a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology. Quest is the largest clinical reference lab to integrate oncology tests in OncoEMR using the opt-in OncoEMR Molecular Profiling Integration (MPI) ordering feature, which is designed to support the specialized test ordering requirements of comprehensive molecular tests. Once completed, the integration will enable 4,700 clinicians across the Flatiron network of 1,600 community-based cancer care locations in the United States to quickly access the Quest services. \"At Flatiron, we're focused on helping oncology teams get the answers they need to deliver the best possible care,\" said Quincy Weatherspoon, Chief Network Officer, US Point of Care, Flatiron Health. \"By integrating...",
    "product": "OncoEMR",
    "summary": "Quest Diagnostics is integrating its Haystack MRD ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers with Flatiron Health's OncoEMR electronic health record.",
    "planning": true,
    "image_url": "https://mma.prnewswire.com/media/2691025/Quest_Diagnostics_questhealth_Logo_v1.jpg?p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "OncoEMR",
      "full_text": "OncoEMR ® , an electronic health record (EHR)",
      "fuzzy_match": false
    },
    "product_tags": [
      "online_technology",
      "medical",
      "data"
    ],
    "published_at": "2026-07-08T12:52:00Z",
    "article_sentence": "Quest Diagnostics (NYSE: DGX ), a leading provider of diagnostic information services, today announced it is integrating its Haystack MRD ® ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR ® , an electronic health record (EHR) from Flatiron Health, via a pilot program with American Oncology Network (AON) and other community oncology providers.",
    "related_company_name": "Flatiron Health",
    "related_company_domain": "flatiron.com"
  }
}

curl https://signals.autobound.ai/v1/signals/146d7ea1-a27e-eec3-916f-dcf6eaad30b1 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"questdiagnostics.com","limit":20}'